Skip to content
Sexuality – Lifestyle
Author:
Thryv Therapeutics Inc.
Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Efficacy Cohort Fully Enrolled in Long QT Syndrome
November 3, 2026
Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure
September 15, 2026
Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain’s CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease
September 3, 2026
Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences
May 12, 2026